Age-Related Macular Degeneration Clinical Trial
Official title:
An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198
Background:
- Alzheimer s disease affects the brain and causes memory and thinking problems in older
people. Macular degeneration (MD) is an eye condition. It is the leading reason that people
over age 55 in the United States lose their central vision. Central vision is important for
seeing fine details and for tasks like reading and driving. A feature of Alzheimer s disease
is plaques in the brain. A feature of age-related MD is deposits in the retina in the eye.
Researchers want to learn more about these diseases and find out if they are related.
Objective:
- To see whether there is a relationship between Alzheimer s disease and age-related macular
degeneration.
Eligibility:
- People with or without Alzheimer s disease enrolled in another study. Participants must
have someone to help them take part in this study.
Design:
- Participants will be screened through the other study. They will have 1 visit. The tests
will take about 3 hours.
- Participants will answer questions about their medical and eye history.
- Participants will have an eye exam to test how well they see. Their eye pressure will be
measured and their eye movements will be checked.
- Participants will get eye drops to dilate their pupils. Researchers will take pictures
of the retina and the inside of the eye. Researchers may measure the thickness of the
retina.
- Participants will continue to receive care from their regular eye doctor during and
after the study.
Objective:
Age-related macular degeneration (AMD) and Alzheimer s disease (AD) are both
neurodegenerative diseases which affect a similar demographic of patients. Beyond age being a
common risk factor for both diseases, an important common characteristic is a similarity in
pathology findings, specifically, the presence of amyloid (beta) (A(beta)) in the senile
plaques of the AD brain and in the drusen of AMD patients. As both of these diseases are the
cause of significant morbidity of the quickly growing aging population, understanding the
pathogenesis of both and identification of any overlapping pathophysiology will lead to a
better understanding of each disease. The objective of this study is to investigate the
presence of AMD and other neurodegenerative lesions and characterize retinal findings in a
group of participants with well-phenotyped AD.
Study Population:
Up to 150 participants (100 symptomatic, 50 controls) will be recruited from patients already
enrolled and participating in the National Institute of Mental Health (NIMH) study,
09-M-0198, Screening and Evaluation of Patients with Signs and Symptoms of Alzheimer s
Disease.
Design:
This is a single center, cross-sectional, observational study that will include a single eye
clinic visit with eye exam, visual acuity, photography and optical coherence tomography (OCT)
testing.
Outcome Measures:
The primary outcome is the presence of AMD or other retinal findings in patients diagnosed
with AD. Secondary outcomes will include autofluorescence imaging, spectral domain OCT and
visual acuity.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |